Capstan Medical Welcomes Marshall Mohr to Its Board to Enhance Heart Valve Treatments

Marshall Mohr Joins Capstan Medical Board of Directors

Capstan Medical, based in Santa Cruz, California, is renowned for developing robotic-enabled solutions targeting heart valve diseases with minimally invasive techniques. In a significant development, the company has announced the appointment of Marshall Mohr to its Board of Directors. This strategic move aims to further Capstan's commitment to bringing innovative healthcare solutions to a broader range of patients.

Marshall Mohr has a long-standing career in the medical technology sector. He joined Intuitive Surgical in 2006, where he made remarkable contributions as Senior Vice President and Chief Financial Officer, leading the company through a trajectory of unparalleled growth. His leadership helped position Intuitive Surgical as a world leader in robotic-assisted minimally invasive surgery. Beyond his role in financial management, Mohr also served as Executive Vice President of Global Business Services, where he broadened the company’s operational infrastructure and commercial strategies globally.

Mohr’s insights into the industry will be particularly valuable for Capstan as it seeks to address the pressing needs of heart valve disease patients. “Capstan’s platform is tackling an unserved area of cardiovascular care for a patient population that has almost no other options,” he remarked. Mohr believes that Capstan’s approach has the potential to transform heart valve disease treatment into precise, low-stress procedures for both patients and healthcare providers.

Maggie Nixon, the CEO of Capstan Medical, also expressed her enthusiasm for Mohr’s appointment, highlighting the importance of having a knowledgeable team in place. She stated, “Having the right team and the right technology is foundational to everything we do at Capstan Medical.” Her previous experiences witnessing Mohr’s success in the MedTech field have left her confident in the strategic direction of the company as it moves forward.

Capstan Medical recently achieved a significant milestone with an oversubscribed $110 million Series C funding round, which was a vote of confidence in their pioneering approach to heart valve interventions. In early 2025, they successfully completed the first-ever robotic-assisted transcatheter mitral valve replacements in human trials, marking a groundbreaking moment for minimally invasive surgery. This innovative procedure was a monumental step, offering hope to many patients facing the daunting prospect of traditional open-heart surgery.

With over 7 million individuals in the U.S. living with heart valve disease, the need for effective treatment solutions has never been more urgent. The current treatment options are often fraught with complications and are not viable for a large population, especially those at high risk for surgery. Capstan Medical seeks to change this narrative by introducing advanced technology and novel heart valve implants that are operated through an intuitive robotic platform.

As the healthcare community looks towards a future where robotic interventions become a standard for treating complex conditions like heart valve disease, the addition of experienced leaders like Mohr on the board is viewed as essential for navigating challenges and advancing Capstan's mission. With a foundation built on innovation and a genuine concern for patient care, Capstan Medical is well on its way to establishing a new standard in heart valve interventions.

For more information about Capstan Medical and their innovations, visit www.capstanmedical.com.

Source: Capstan Medical